reports
Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ
Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ End-of-day, Thursday, May 2, 2024, Will be the Last and Final Day to Trade SAVAW Warrants on NASDAQ.Monday, May 6, 2024, Will be the Last and Final Day to Cash-Exercise SAVAW Warrants.‘Notice of Guaranteed Delivery’ Is Available for Warrant Exercises. AUSTIN, Texas, May 01, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA) (“Cassava Sciences” or the "Company") has been advised by NASDAQ that end-of-day (“EOD”) tomorrow May 2, 2024, will be the last and final trading day for SAVAW warrants on NASDAQ. After EOD May 2, the ...
Redemption Date Announced for Warrants
Redemption Date Announced for Warrants Monday, May 6, 2024 is Last and Final Day to Exercise Warrants.Once Redeemed, the Warrants Will Cease to Exist and Have No Value. AUSTIN, Texas, April 15, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (“Cassava Sciences” or the "Company") today announced that Monday, May 6, 2024 is the last and final day to exercise the warrants that were previously distributed to its shareholders on January 3, 2024 (the “Warrants”). Holders who exercise their Warrants will receive 1.5 shares of Cassava Sciences’ common stock per Warrant, for an eff...
- Gary Brode
Moody's Ratings affirms J&J's Aaa ratings; stable outlook
Moody's Ratings (Moody's) affirmed the ratings of Johnson & Johnson ("J&J") including the Aaa long-term issuer rating, Aaa senior unsecured rating, (P)Aaa senior unsecured medium term note program rating and Prime-1 commercial paper rating. The outlook remains stable. This rating action follows th...
Cassava Sciences Announces Completion of an Interim Safety Review of O...
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials. The DSMB Recommended Both Phase 3 Trials Continue as Planned, Without Modification. Final Clinical Safety Data for Simufilam Are Expected at the Conclusion of the Phase 3 Program. AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzhe...
Abbvie Inc: 1 director
A director at Abbvie Inc sold 21,082 shares at 176.300USD and the significance rating of the trade was 76/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
Johnson & Johnson: 1 director
A director at Johnson & Johnson sold 8,891 shares at 162.160USD and the significance rating of the trade was 79/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 Int...
Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced plans to present a virtual oral presentation at the International Conference on Alzheimer’s and Parkison’s Disease (AD/PD 2024) taking place in Lisbon, Portugal from March 5-9, 2024. Presentation details Title: Oral Simufilam in Mild-to-moderate Alzheimer’s Disease: Baseline Characteristics in RETHINK and REFOCUS Phase 3 Tr...
Cassava Sciences Reports Full-year 2023 Financial Results and Corporat...
Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates $121.1 Million In Cash and Cash Equivalents at December 31, 2023, With an Additional $21.8 Million Raised In 2024 From Exercise of Warrants.A Total of Over 555 Study Participants Have Completed Our Phase 3 Studies.Topline Data Readout for Our 52-Week Phase 3 Trial Expected Year-End 2024.Internal Investigation by Outside Counsel Has Found No Evidence to Substantiate Allegations of Research Misconduct by the Company. AUSTIN, Texas, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biote...
No Decline in Cognition Scores in Patients with Mild Alzheimer's Disea...
No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months ADAS-Cog Scores Were Stable in a Group of Patients with Mild Alzheimer’s Who Received Drug Candidate Simufilam Continuously, Baseline to Month 24.Mild Alzheimer’s Patients Who Received Simufilam Non-Continuously Declined a Group Average of 1 Point on ADAS-Cog, Baseline to Month 24.Oral Simufilam Safe, Well-Tolerated. AUSTIN, Texas, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today reported top-line results of a tw...
- MarketLine Department
Saponia dd - Company Profile and SWOT Analysis
Summary Saponia dd - Company Profile and SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Saponia dd (Saponia) is a manufacturer of home care and personal hygiene products. The company’s product portfolio comprises dish detergents, laundry detergents, toothbrushes, baby care, hand cream, shaving ...
Cassava Sciences Completes Dividend Distribution of Warrants to Shareh...
Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders Shareholders of Record Received Warrants to Purchase Shares of Common Stock Warrants Trade on Nasdaq Under the Ticker “SAVAW”Warrant Holders Who Choose to Exercise During an Early Period Will Receive an Additional 0.5 of a Common Share Per Warrant AUSTIN, Texas, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) ("Cassava Sciences" or the "Company") today announced the completion of a previously announced distribution of warrants (the “Warrants”) to its shareholders. The Warrants now tra...
- Dave Nicoski
- Ross LaDuke
ANTM ANTHEM INC.
TSN TYSON FOODS INC. CLASS A
RYAM RAYONIER ADVANCED MATERIALS INC
RY. ROYAL BANK OF CANADA
MRK MERCK & CO. INC.
LAZ LAZARD LTD CLASS A
KHC KRAFT HEINZ COMPANY
K KELLOGG COMPANY
GIS GENERAL MILLS INC.
GILD GILEAD SCIENCES INC.
FIBK FIRST INTERSTATE BANCSYSTEM INC. CLASS A
CVS CVS HEALTH CORPORATION
CPB CAMPBELL SOUP COMPANY
CNC CENTENE CORPORATION
CF CF INDUSTRIES HOLDINGS INC.
CAG CONAGRA BRANDS INC.
BGS B&G FOODS INC.
ARWR ARROWHEAD PHARMACEUTICALS INC.
ABUS ARBUTUS BIOPHARMA CORP.
VIRT VIRTU FINANCIAL INC. CLASS A
FDP FRESH DEL MONTE PRODUCE INC.
CENX CENTURY ALUMINUM COMPANY
KMI KINDER MORGAN INC CLASS P
KO COCA-COLA COMPANY
LMT LOCKHEED MARTIN CORPORATION
SJM J.M. SMUCKER COMPANY
ABBV ABBVIE INC.
MRNA MODERNA INC.
VTRS VIATRIS INC.
RLAY RELAY THERAPEUTICS
RNA AVIDITY BIOSCIENCES
DOLE DOLE PLC
Cassava Sciences Announces Dividend Distribution of Warrants to Shareh...
Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders Shareholders of Record Will Receive Warrants to Purchase Shares of Common Stock All Warrants to Be Distributed to Shareholders Free of ChargeWarrants Are Expected to List and Trade on NasdaqWarrant Holders Who Choose to Exercise During an Early Period Will Also Receive an Additional 0.5 of a Common Share Per Warrant AUSTIN, Texas, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) ("Cassava Sciences" or the "Company") today announced a pro rata dividend distribution of warrants to holders ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.